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INTRODUCTION
BMT is the only curative therapy available for several
hematologic malignancies. The most significant limitation
to the transplantation of bone marrow across MHC barri-
ers is GVHD. Although T cell depletion of donor marrow
has successfully reduced the incidence of acute GVHD, it
has also resulted in increased rates of failure of engraftment
[1] and relapse of chronic myelogenous leukemia [2,3].
Lower relapse rates and improved survival after allogeneic
BMT for acute leukemia have been observed in patients
who develop chronic GVHD [4]. Both acute and chronic
GVHD are associated with decreased relapse rates in
patients with acute nonlymphocytic leukemia, acute lym-
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ABSTRACT
Mixed hematopoietic chimerism can be induced in mice receiving allogeneic bone marrow transplantation (BMT)
after nonmyeloablative host conditioning with depletion T cells with of anti–T cell monoclonal antibodies (mAbs),
low-dose (3 Gy) total-body irradiation (TBI), and local thymic irradiation (7 Gy). These mice are specifically toler-
ant to donor and host antigens. When nontolerant donor T cells are given to chimeras several months after BMT,
full donor-type chimerism develops, but graft-vs.-host disease (GVHD) does not occur. The induction of such lym-
phohematopoietic GVH reactions without GVHD could provide an approach to separating graft-vs.-leukemia
(GVL) from GVHD in patients with hematologic malignancies. To make the nonmyeloablative conditioning regi-
men described above more cytoreductive for such malignancies, we have now modified it by replacing TBI with
cyclophosphamide (CP). Treatment with anti-CD4 and anti-CD8 mAbs on day –5, 200 mg/kg CP on day –1, and 7
Gy thymic irradiation on day 0 was only slightly myelosuppressive and allowed fully major histocompatibility com-
plex (MHC)-mismatched (with or without multiple minor antigen disparities) allogeneic bone marrow to engraft
and establish long-term mixed chimerism in 40 to 82% of recipients in three different strain combinations. The
administration of nontolerant donor spleen cells at 5 weeks or at 5, 8, and 11 weeks posttransplant was capable of
eliminating host hematopoietic cells, leading to full or nearly full donor chimerism in six of six and two of four
chimeric animals in two different strain combinations. No clinical evidence of GVHD was observed in any recipients
of these donor leukocyte infusions (DLI). These studies demonstrate that induction of mixed chimerism with non-
myeloablative conditioning followed at appropriate times by DLI might allow lymphohematopoietic GVH reactions,
and hence GVL effects, to eliminate chronic hematologic malignancies without causing clinically significant GVHD. 
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phocytic leukemia, and chronic myelogenous leukemia [5].
Thus, host-reactive donor T cells can eliminate host cells
that resist alloengraftment [6] and can also eliminate resid-
ual tumor cells. In patients with hematologic malignancies,
such GVL effects are a major potential benefit of allogeneic
BMT and might be further augmented if HLA-mismatched
BMT could be performed routinely without excessive
GVHD. 
Mixed hematologic chimerism, the coexistence of two
genetically different types of bone marrow, can be induced
with lethal irradiation followed by BMT with a mixture of
T cell–depleted host-type and allogeneic marrow cells [7].
Mixed chimerism also can be induced with allogeneic BMT
after nonmyeloablative host conditioning, such as a regimen
that includes anti-CD4 and anti-CD8 monoclonal antibod-
ies (mAbs) on day –5, followed by 3 Gy TBI and 7 Gy
thymic irradiation on day 0. Mixed chimerism is associated
with a state of donor- and host-specific transplantation tol-
erance [8], which is induced by an intrathymic deletional
mechanism [9]. In these mice, GVHD is not induced by
T cells present in the initial marrow inoculum because these
are eliminated by anti-CD4 and anti-CD8 mAbs that persist
in the recipient’s serum for 1 to 3 weeks after BMT [10].
When nontolerant donor spleen cells were administered
to stable mixed chimeras prepared with lethal irradiation
and mixed syngeneic and allogeneic marrow transplants,
complete repopulation with allogeneic cells ensued [11].
This lymphohematopoietic GVH reactivity exhibited by
donor spleen cells was not accompanied by clinically evident
GVHD. Similar to these results in mixed chimeras prepared
with lethal irradiation [11], delayed DLI to mixed chimeras
prepared with the previously described nonmyeloablative
regimen could convert them to full donor-type chimeras
without causing GVHD [M.G. Wang and M.S., unpub-
lished data].
We hypothesized that the establishment of mixed
chimerism and specific transplantation tolerance through
a nonmyeloablative regimen and the subsequent lympho-
hematopoietic GVH reactions induced by delayed leuko-
cyte infusions might be exploited to treat indolent hema-
tologic malignancies,  such as chronic lymphocytic
leukemia, in which immediate cytoablation by chemo-
therapy or radiotherapy (or both) would not be essential
for survival. These diseases often afflict older persons who
are subject to a high risk of complications after conven-
tional BMT but who might be better able to tolerate a less
toxic, nonmyeloablative conditioning approach. We
hypothesized further that GVHD might not be induced
by infusions given after a sufficient delay to recipients
originally conditioned with a mild regimen and that this
might be a useful approach to separating lymphohe-
matopoietic GVH reactions, which can mediate potent
GVL effects, from GVHD. We have now developed a
cyclophosphamide (CP)-based, nonmyeloablative BMT
treatment strategy that would be expected to have cytore-
ductive activity for a variety of hematologic malignancies
and that allows the induction of mixed bone marrow
chimerism. The ability of delayed donor leukocyte infu-
sions to mediate lymphohematopoietic GVH reactions
without causing GVHD, which could have potential as
antileukemic immunotherapy, was evaluated. 
MATERIALS AND METHODS
Animals
B10.BR (H-2k) male and female donor mice purchased
from the Jackson Laboratory (Bar Harbor, ME) were used at
7 to 12 weeks of age. Female BALB/c (H-2d) recipient mice
were purchased from Frederick Cancer Research Facility,
National Cancer Institute, and used after 8 weeks of age. In
other experiments, B10.A or A/J donors (both H-2a, KkIkDd),
and C57BL/6 (B6) (H-2b) recipients, all purchased from the
Frederick Cancer Research Facility, were used. All mice were
housed in autoclaved microisolator environments, and all
manipulations were performed in a laminar flow hood. 
Preparation of chimeras
Control chimeras were prepared using our standard
nonmyeloablative regimen, as previously described [8], and
are referred to as “standard nonlethal regimen” (NLR)
chimeras. Recipient BALB/c or B6 mice were treated on day
–5 with depleting anti-CD8 mAb 2.43 [12] (1.4 mg) and
depleting anti-CD4 mAb GK1.5 [13] (2.0 mg) intraperi-
toneally (i.p.) in sterile Hanks’ balanced salt solution as
described. On day 0, recipient mice were treated with 7 Gy
thymic irradiation from a cobalt-60 source and 3 Gy TBI
from a cesium-137 source. CP chimeras were prepared
identically except that CP was given instead of TBI. 
CP (Mead Johnson and Pharmacia) was reconstituted
using sterile water to a concentration of 20 mg/mL up to 24
hours before injection. Reconstituted CP was stored in
polypropylene tubes as directed. On day –1, mice received
100 mg/kg or 200 mg/kg cyclophosphamide i.p.
Bone marrow was harvested and single-cell suspensions
were prepared as described previously [14]. Approximately 4
hours after the completion of irradiation, each recipient was
injected intravenously through a tail vein with 14–203106
donor bone marrow cells (BMC). 
Flow cytometric analysis of peripheral white blood cells
and hematopoietic tissues
Chimerism was assessed by two-color flow cytometry
(FCM) using a Becton Dickinson (Mountain View, CA)
FACScan cytometer. After preparation of white blood cells
(WBC) by deionized water lysis, cells were incubated with
monoclonal antibodies. To reduce nonspecific mAb binding,
anti-Fc receptor mAb 2.4G2 [15] was added to all tubes.
Cells were stained as described [16] with HOPC1-fluores-
cein isothyocyanate (FITC) (a nonreactive control antibody
prepared in our laboratory); biotinylated (BIO) anti-H-2Dd
mAb 34-2-12 [17], FITC-conjugated anti-H-2Kk mAb 36-7-
5 [18], FITC-conjugated anti-H-2Kb antibody 5F1 [19], or
FITC-conjugated anti-Db mAb KH95 (Pharmingen, San
Diego, CA); and phycoerythrin (PE)-conjugated anti-CD4
and anti-CD8 mAbs or PE-conjugated rat IgG2a (a nonreac-
tive control antibody) purchased from Pharmingen. Staining
by BIO mAbs was developed by incubation with FITC-con-
jugated avidin (FA) for 10 minutes followed by washing. Pro-
pidium iodide, which is taken up by dead cells, was added to
all tubes immediately before FACScan analysis to allow gat-
ing of live cells. Ten thousand live events were collected and
analyzed. Lymphocyte, monocyte, and granulocyte popula-
tions were distinguished using forward-by-side scatter dot
plots in combination with staining of control cells with mAb
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Mac1. For quantitative analysis, percentages of positive cells
were determined using the following formula: 
(chimera % positive – negative control % positive)
3 100%
(positive control % positive – 
negative control % positive)
after values were corrected by subtraction of cells staining non-
specifically with nonreactive control mAbs. For each H-2 class
I allele-specific mAb, the mouse strain (donor or host) not
bearing the allele recognized by the mAb was the negative con-
trol and the strain expressing the allele was the positive control.
In some studies, WBC analysis was performed by staining with
FITC-labeled anti-IgM or B220 (Pharmingen) to detect
B cells, anti-CD4 or anti-CD8 to detect T cell subsets, and
Mac1 mAb to detect myeloid cells, vs. BIO H-2 allele-specific
mAb, plus phycoerythrin-streptavidin (PEA). In these studies,
the percentage of donor cells among B cells and T cell subsets
was determined in the lymphoid gate, and that among Mac1-
positive cells was determined in the granulocyte and monocyte
gates. Control staining with irrelevant mAb HOPC-1 or rat
IgG2a was subtracted from the percentage of donor and host-
type cells detected in each quadrant of a two-color dot plot.
Percentages of donor-derived cells in each marker-positive sub-
population were calculated as the fraction of all cells in that
subpopulation that were donor-derived multiplied by 100%.
For analysis of bone marrow, splenocyte, and thymocyte
populations, single-cell suspensions were prepared, and two-
color FCM was performed using anti-donor class I–specific
mAb vs. rat anti-mouse IgM or B220 mAb, anti-CD4 and
CD8 mAbs, and Mac1 mAbs. Control staining with irrele-
vant mAb HOPC-1 or rat IgG2a was subtracted from the
percentage of donor- and host-type cells detected in each
quadrant of a two-color dot plot. Percentages of donor-
derived splenic CD4, CD8, and B cells were calculated as
the fraction of all cells in each population that were donor
derived multiplied by 100%. Percentages of donor-derived
bone marrow cells and thymocytes are reported as the net
percentage of cells staining with donor class I–specific mAb.
Complete blood counts 
Peripheral blood samples obtained from tails were collect-
ed in heparin-coated Eppendorf tubes. Samples were diluted in
diluent buffer and analyzed by a Serono Baker 9000 automated
complete blood count (CBC) instrument (Allentown, PA).
Results are presented as mean values with standard deviations. 
Donor spleen cell infusions to mixed chimeras
Chimeras were prepared as described above. Peripheral
blood chimerism was assessed by FCM on day 14. Using these
results, similar groups of CP chimeras were chosen on the basis
of the level of donor repopulation and the presence or absence of
donor T cells. Intravenous injections of 303106 spleen cells from
mice syngeneic to the original marrow donor strain were given at
day 35 and, where indicated, at 8 and 11 weeks. Spleens were har-
vested under sterile conditions, red cells were lysed in ACK lysing
buffer, and single-cell suspensions were prepared and counted. 
Statistical analysis
Group means were compared using Student’s t test. A p
value <0.05 was considered significant.
RESULTS
Effects on hematopoiesis of conditioning with a CP-based
nonmyeloablative regimen
To determine whether CP could replace TBI for the
induction of mixed chimerism in a nonmyeloablative regi-
men that includes host T cell depletion and thymic irradia-
tion, we transplanted fully MHC and multiple minor histo-
compatibility antigen–mismatched marrow to mice receiv-
ing 100 mg/kg or 200 mg/kg CP in place of 3 Gy TBI.
BALB/c mice were conditioned with anti–T cell mAbs on
day –5, CP at 100 mg/kg or 200 mg/kg on day –1, and
thymic irradiation (7 Gy) on day 0. They were then either
left untreated or given B10.BR BMC on day 0. A control
group received our standard NLR, in which 3 Gy TBI is
given on day 0 instead of CP. These mice received B10.BR
BMT similar to the standard NLR [8]. Both CP-based regi-
mens were nonmyeloablative, as all animals survived, even
without BMT. CBCs were performed at early time points,
and mean values with standard deviations for each group are
presented in Fig. 1. Although a transient decline in WBC
counts was observed on day 4 in recipients of either CP
dose, these counts recovered to just below the normal range
by day 7. The group receiving the TBI-containing standard
NLR showed persistence of the marked depression in WBC
counts at day 7, whereas WBC counts in CP-treated mice
had increased substantially above their nadir. In CP-treated
mice, no differences were observed in the WBC nadir or in
the rate of recovery in animals receiving BMT compared
with those receiving conditioning alone, and a CP dose
effect was not apparent. All of the groups recovered normal
WBC counts by 27 to 42 days after BMT (Fig. 1). None of
the CP-treated groups, regardless of whether BMT was
given, showed significant declines in hemoglobin concentra-
tions, with the exception of a slight and transient decrease
on day 7 in recipients of 100 mg/kg CP plus BMT (Fig. 1,
middle panel). The group that received the standard 3-Gy
TBI-containing regimen without CP showed a significant
decline in platelet count on day 7, but this recovered to nor-
mal levels by day 14. CP-treated groups did not show
significant reductions in platelet counts in this period (Fig.
1, bottom panel).
Mixed chimerism in recipients of CP-based conditioning
Two-color FCM analysis was performed on peripheral
WBC to determine the level of donor reconstitution in
various lymphoid and myeloid lineages over time in the
BMT groups receiving CP-based conditioning. Variable
levels of donor reconstitution were detected in mice
receiving the two different CP doses (Fig. 2). Although
persistent chimerism developed in only one of five mice
receiving BMT after anti–T cell mAbs, thymic irradiation,
and 100 mg/kg CP, higher rates were achieved in the
group that received 200 mg/kg CP. Four of five mice in
this group showed chimerism for the first 6 weeks after
BMT, and three of these animals showed persistent
chimerism at the last day of follow-up, between 10 and 31
weeks posttransplant. All chimeras conditioned with the
CP-based regimen showed higher levels of donor reconsti-
tution in the lymphoid than in the myeloid lineages, with
only minimal granulocyte and monocyte chimerism
detectable (Fig. 2).
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In two repeat experiments, persistent multilineage
WBC chimerism (follow-up 6 to 17 weeks) was achieved in
six of nine mice receiving the regimen containing 200
mg/kg CP. Combining all three experiments, the overall
persistent WBC chimerism rate was 64% in mice receiving
this regimen. Mice were killed at 9 and 12 weeks post-BMT
to allow evaluation of chimerism in additional lymphohe-
matopoietic tissues. Data from representative animals are
presented in Fig. 3. Five of five animals showed measurable
chimerism to varying degrees in some or all of the thymus,
spleen, lymph node, and marrow. One animal killed at 9
weeks had already shown a loss of WBC chimerism by 7
weeks post-BMT and had low levels of donor T and B cells
in the spleen and lymph node but did not show marrow or
thymic chimerism. A second animal killed at 12 weeks (ani-
mal 1 in Fig. 3), which had declining but measurable WBC
chimerism at 11 weeks, showed a similar pattern of
chimerism. The other three CP-chimeras, which had shown
higher levels of WBC chimerism before death, all showed
significant chimerism among splenic and lymph node T and
B cells and low but measurable donor representation among
mature thymocytes and bone marrow cells (e.g., animals 2
and 3 in Fig. 3).
To determine whether chimerism could be achieved with
a CP-based regimen in additional strain combinations, we
performed transplants in the B10.A to B6 (full MHC dispari-
ty) and A/J to B6 (full MHC plus multiple minor antigen dis-
parities) strain combinations using the higher-dose CP-based
conditioning regimen. In the B10.A to B6 combination, last-
ing WBC chimerism developed in a total of nine of 11 recip-
ients in two separate experiments followed up to 25 weeks
(data not shown). The chimerism rate was somewhat lower
in the A/J to B6 combination, with a total of four of 10 ani-
mals showing lasting (up to 25 weeks) chimerism in two sep-
arate experiments (data not shown). In both strain combina-
tions, similar to results described above for the B10.BR to
BALB/c combination, chimerism was higher in the lymphoid
lineages than in the myeloid lineages.
Animals in both the B10.A fi B6 and A/J fi B6 strain
combinations were killed 21 to 28 weeks post-BMT. As
shown in Table 1, six of nine A/J fi B6 and seven of seven
B10.A fi B6 chimeras showed the presence of donor T
Figure 1. 
Complete blood counts of BALB/c mice receiving T cell–depleting monoclonal
antibodies on day –5, 7 Gy thymic irradiation on day 0, and 3 Gy TBI on day
0 (NLR control), 100 g/kg cyclophosphamide (CP) on day –1, or 200 mg/kg
CP on day –1, with or without allogeneic B10.BR bone marrow transplanta-
tion (BMT). Groups that received BMT are indicated in the figure legend. In
addition, the NLR control group also received BMT. *p < 0.05 compared with
untreated BALB/c controls (n=6). Similar results were obtained in a second
experiment in which the 100 mg/kg CP dose was tested.
Figure 2. 
Chimerism in lymphocyte and granulocyte populations in white blood cells of
BALB/c mice receiving B10.BR bone marrow transplantation after condition-
ing with T cell–depleting monoclonal antibodies on day –5, 7 Gy thymic irradi-
ation on day 0, and 100 mg/kg or 200 mg/kg cyclophosphamide (CP) on day
–1. Each symbol represents an individual animal followed over time. Similar
results were obtained in one additional experiment involving the 100-mg/kg
CP dose and two additional experiments involving the 200-mg/kg dose.
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and/or B cells in the spleen at the time of sacrifice; five of
nine and four of nine, respectively, showed thymic
chimerism, and six of nine and seven of seven, respectively,
showed low levels of marrow chimerism at the time of
death. 
Donor leukocyte infusions beginning at 5 weeks can
increase chimerism without inducing clinical GVHD
We next evaluated the ability of delayed donor leuko-
cyte infusions (DLI) to eliminate host-type hematopoietic
cells without causing GVHD. BALB/c mice received anti–T
cell mAbs on day –5, 200 mg/kg CP on day –1, and 7 Gy
thymic irradiation on day 0, followed by 203106 B10.BR
donor BMC on day 0. Three groups of animals (n=3 each)
with similar levels of chimerism were selected, and B10.BR
donor-type spleen cells (33107) were administered at vari-
ous times thereafter to two of the three groups. As shown in
Fig. 4, DLI at 5 weeks resulted in a dramatic increase in
repopulation by donor cells in three of three animals, which
was evident in all lineages by 10 weeks post-BMT and per-
sisted at 16 weeks post-BMT. Multiple DLI at weeks 5, 8,
and 11 post-BMT also led to conversion to complete donor
repopulation in the monocyte and granulocyte lineages by
10 weeks post-BMT in three additional chimeras. While
host monocytes, granulocytes, and most B cells (not shown)
had been eliminated by 16 weeks in mice receiving DLI at 5
weeks and those receiving DLI at 5, 8, and 11 weeks, elimi-
nation of host T cells after DLI occurred more slowly. In
these mice, up to 40% of all T cells were still of host origin
at 16 weeks. Overall, compared with non-DLI controls in
the same experiment, a dramatic increase in donor reconsti-
tution was seen in six of six mice receiving DLI (Fig. 4). The
fact that conversion occurred in all lineages, including
myeloid cells that turn over rapidly, indicates that the
increase in donor WBC reflected a change in the balance of
donor vs. host hematopoiesis rather than mere expansion of
the T cells administered in the DLI.
Two recipients each of single DLI (at 5 weeks) and of
multiple DLI (at 5, 8, and 11 weeks), were killed more than
a year after BMT (~14 months). All of these animals showed
complete donor reconstitution among splenic T and B cells.
Both recipients of multiple DLI and one recipient of a sin-
gle DLI showed full donor marrow repopulation, but one
recipient of a single DLI still contained about one-third
host-derived cells in the marrow at the time of sacrifice. No
evidence of lymphoid atrophy, which could be a subtle man-
ifestation of GVHD, was seen, as lymphoid tissues were
similar in size to those of mice of the same age killed at the
same time (data not shown). Unfortunately, all of the non-
DLI CP chimeras had died by this time and were not avail-
able for chimerism analysis.
One non-DLI chimera in this experiment died on day
61 of unknown cause. All DLI recipients survived and
showed no clinical evidence of GVHD. As shown in Fig. 4,
there was no difference in the weights of the mice receiving
DLI compared with the non-DLI controls. Thus, donor
leukocyte infusions given at 5 weeks or at 5, 8, and 11 weeks
led to a significant lymphohematopoietic GVH reaction that
was associated with destruction of host-type hematopoietic
cells without causing clinically significant GVHD.
We also evaluated the effect of DLI in the A/J fi B6
strain combination. Six A/Jfi B6 BMT recipients were given
DLI on day 35 post-BMT. Two of these mice had already
lost chimerism in most lineages before DLI, and these did
not recover any measurable chimerism after DLI. Two addi-
tional mice still had low levels of chimerism at 4 weeks and
did not show an increase in chimerism after DLI. Both of
these mice eventually lost WBC chimerism (Fig. 5). Finally,
the two mice showing the highest levels of chimerism at 4
weeks, before DLI, converted to become full donor
chimeras by about 7 to 10 weeks post-BMT. One of these
animals remained fully donor-type in all lineages, whereas
the other later developed “split” chimerism, with the
Figure 3. 
Chimerism in bone marrow, spleen, and thymus 12 weeks after bone marrow
transplantation (BMT) of BALB/c mice that received T cell–depleting mono-
clonal antibodies on day –5, 7 Gy thymic irradiation on day 0, and 200 mg/kg
cyclophosphamide on day –1, followed by B10.BR BMT on day 0. Top panel:
thymic chimerism. Middle panel: splenic chimerism. , percent donor CD4
cells; , percent donor CD8 cells; , percent donor B cells. Data are normal-
ized to 100% for each lineage, so that donor- plus host-derived cells total
100%. Bottom panel: Bone marrow chimerism. , percent donor-derived cells
among low forward scatter/low side scatter cell population; , percent donor-
derived cells in high forward scatter/high side scatter cell population. Results
from individual animals shown here are similar to those obtained for animals
sacrificed at 9 weeks post-BMT (not shown).
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appearance of ~50% host-derived myeloid cells and 12%
host-derived B cells at 14 weeks, while CD4 (Fig. 5) and
CD8 (not shown) T cells remained fully donor in origin.
Non-DLI controls in the same experiment did not show an
increase in donor repopulation over time (e.g., an average of
12.1, 15.8, 1.1, 4.5, and 3.9% of WBC CD4 cells, CD8
cells, B cells, granulocytes, and monocytes, respectively,
were donor derived at 18 weeks; n=4), indicating that the
DLI was responsible for this increase.
The animals receiving DLI at 5 weeks, which increased
Table 1. Chimerism in tissues of A/Jfi B6 and B10.Afi B6 bone marrow transplant recipients
Percent Dd+
Spleen
CD4 CD8 B cells Thymus Marrow
A/J controls (n=5)* 99.9 ± 0.2 98.9 ± 1.6 99.9 ± 0.2 64.5 ± 12.8 93.4 ± 4.9
B10.A controls (n=6)* 99.9 ± 0.2 99.6 ± 0.9 99.9 ± 0.2 63.6 ± 13.0 95.4 ± 4.7
B6 controls (n=12–13)* 0.6 ± 1.1 0.1 ± 0.3 1.2 ± 1.4 0.2 ± 0.4 0.7 ± 1.9
A/J fi B6 BMT‡ 31.5 ± 35.4 24.4 ± 40.5 29.2 ± 30.0 11.7 ± 6.9 12.7 ± 13.3
Chimeras/total† 6/9 5/9 3/9 4/9 4/9
B10.Afi B6 BMT‡ 9.7 ± 6.5 3.4 ± 2.3 9.4 ± 3.6 4.9 ± 5.1 5.5 ± 5.4
Chimeras/total† 6/7 5/7 7/7 4/7 7/7
Data are mean ± SD.
*Controls are untreated mice of the indicated strain that were analyzed at the time the mixed chimeras included in Table 1 were killed.
†Number of animals showing chimerism/total number of animals analyzed. Chimerism is defined as having % Dd+ cells more than 2SD above the mean for B6
controls.
‡Mean % Dd+ cells for animals defined as showing chimerism.
Figure 4. 
Effect of day 35 donor lymphocyte infusions (DLI) in mixed chimeras prepared with the CP-based regimen in the B10.BRfi BALB/c strain combination. In a sin-
gle experiment, animals received no DLI (n=3), DLI at 5 weeks (n=3), or repeated DLI at 5, 8, and 11 weeks (n=3). Chimerism in the T cell (CD4 plus CD8
positive) and granulocyte populations of white blood cells is shown. Mean weights are shown for each group in the upper right panel. For the group that received a
single DLI at 5 weeks, p < 0.05 for granulocytes at 10 weeks and 17 weeks, and for T cells at 17 weeks, compared with the group not given DLI. For the group
that received repeat DLI, p < 0.05 at 10 and 17 weeks compared with the no-DLI group for both T cells and granulocytes.
y p p f
139B B & M T
their level of donor chimerism, showed perfect health through-
out the experiment, with no weight loss or clinical evidence of
GVHD (Fig. 5). Thus, DLI at 5 weeks could convert a subset
of mixed chimeras to full donor chimeras in the A/Jfi B6 strain
combination without causing clinically significant GVHD.
However, conversion to full donor chimerism occurred only in
the animals showing the highest levels of chimerism shortly
before the time of DLI (Fig. 5). At the time of death 26 weeks
posttransplant, spleen cell yields were similar to those of con-
trols not receiving DLI, but thymocyte yields were lower than
those of controls in one of two DLI mice that converted to full
chimerism, raising the possibility that the GVH reaction may
have induced thymic atrophy in this animal.
DISCUSSION
In the studies reported here, we have modified a previ-
ously established nonmyeloablative method of inducing
mixed chimerism by using CP in place of low-dose TBI in
the conditioning regimen. The original regimen on which
the present studies were based was developed for the pur-
pose of inducing mixed chimerism and transplantation tol-
erance while avoiding the use of toxic, myeloablative
chemoradiotherapy [8]. The goal of the present studies was
to modify the regimen to make it applicable to the treat-
ment of patients with chronic hematologic malignancies.
Successful engraftment of donor marrow after conditioning
with a milder, nonmyeloablative conditioning regimen
might be used to set the stage for donor leukocyte infusions
as immunotherapy. Infusions of donor leukocytes that con-
tained large numbers of T cells converted mixed chimeras
prepared with another regimen to full donor-type chimeras,
without causing GVHD [11]. Because the number of T cells
administered in these DLI would have been sufficient to
cause rapidly lethal GVHD in freshly conditioned mice, we
hypothesized that resistance to GVHD increased with time
after conditioning and BMT [11]. A similar demonstration
in mice conditioned with a nonmyeloablative regimen for
the induction of mixed chimerism [M.G. Wang and M. S.,
unpublished data] confirmed that GVH alloreactions direct-
ed at host alloantigens could eliminate host hematopoietic
cells without causing GVHD. “Lymphohematopoietic
GVH reactions” suggested a novel approach to separating
GVHD and GVL. The present studies were aimed at modi-
Figure 5. 
Effect of day 35 donor leukocyte infusions on white blood cell chimerism among CD4 T cells (top left), B cells (top right), and granulocytes (bottom left), and on
weights (bottom right) in CP chimeras prepared in the A/J-B6 strain combination. B6 mice received T cell–depleting mAbs on day –5, 7 Gy thymic irradiation on
day 0, and 200 mg/kg CP on day –1, followed by A/J bone marrow transplantation on day 0. Each line represents an individual animal in all four panels (n=6).
The weight curves are shown with the same symbols used in the chimerism curves. CD8 cells had chimerism patterns (not shown) similar to those of CD4 cells . A
single experiment was performed.
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fying our existing nonmyeloablative conditioning regimen
to include an agent that would be cytoreductive for a variety
of lymphohematopoietic malignancies and at determining
whether delayed DLI could then be used to mediate lym-
phohematopoietic GVH reactions (and hence GVL) with-
out inducing GVHD. 
The results presented here demonstrate that it is possible
to establish and maintain mixed chimerism using a modifica-
tion of our nonmyeloablative regimen that replaces TBI with
CP. The higher dose of 200 mg/kg CP was more successful
in permitting long-lasting multilineage chimerism than was
the lower dose of 100 mg/kg. Although transient and mild
myelosuppression occurred in mice conditioned with this
regimen, the leukopenia was less marked than that observed
in mice receiving our standard TBI-containing nonmyeloab-
lative regimen, and no significant thrombocytopenia, ane-
mia, or other toxicity was observed. Lasting chimerism was
achieved in three different strain combinations involving
BMT across complete MHC barriers, although the success
rate varied from ~40% in the A/Jfi B6 strain combination to
64% in the B10.BR fi BALB/c and 82% in the B10.A fi B6
strain combinations. Because the A/J fi B6 and B10.A fi B6
strain combinations both involved H-2a donors and H-2b
recipients, the non-MHC background of the donor strain or
the presence of multiple minor histoincompatibilities in
addition to complete MHC disparity (or both), influenced
the ability to achieve lasting chimerism. Although this vari-
ability in results in different strain combinations raises con-
cern about the applicability of this approach to outbred
human populations, it should be borne in mind that it is
unlikely that transplantation from fully MHC-mismatched
donors, as we have done in these animal studies, would be
necessitated in humans with hematologic malignancies. Most
individuals have a relative who shares at least one HLA hap-
lotype, and often one or more loci on the second haplotype
also share identical alleles. Thus, it will be important to
repeat our studies in mouse strain combinations differing at
one MHC haplotype or less. We predict that chimerism and
conversion to full donor chimerism with DLI will be more
universally achievable with lesser degrees of MHC disparity. 
In all three strain combinations, higher percentages of
donor cells were observed among the lymphoid lineages
than among monocytes and granulocytes. These results
contrast significantly with those obtained in chimeras pre-
pared with our standard TBI-containing nonmyeloablative
regimen, in which high levels of myeloid chimerism are
achieved and in which B cell and myeloid chimerism are
usually observed at similar levels at steady state [20]. These
results may reflect the higher degree of immunosuppression
achieved with CP compared with 3-Gy TBI, which appears
to be more myelosuppressive (Fig. 1) [21,22]. Selective
depletion of recipient lymphocytes may allow higher levels
of initial reconstitution by donor-derived common lym-
phoid progenitors [23] than by donor myeloid progenitors.
The higher degree of myelosuppression achieved with TBI
probably allows higher levels of donor pluripotent hemato-
poietic stem cell engraftment to be achieved, thus explaining
the higher long-term plateau levels of donor chimerism
achieved with the standard TBI-containing regimen [20,8]
compared with the CP-based regimen described here.
Delayed administration of donor leukocytes at day 35
and later was able to convert some of the mixed chimeras to
full or nearly-full donor-type chimeras without inducing
clinically significant GVHD in any mice. This effect was
more consistent in the B10.BR fi BALB/c strain combina-
tion than in the A/J fi B6 combination, in which the inci-
dence of lasting chimerism tended to be lower in non-DLI
controls. The number of donor T cells administered in the
DLI here is sufficient to cause severe, lethal, acute GVHD
in fresh, lethally irradiated recipients [24–26]. Studies in
fully allogeneic chimeras, which are also resistant to the
induction of GVHD by delayed allogeneic T cell adminis-
tration [11,27–30], indicate that the time available for host
recovery from conditioning treatment is an important factor
in determining resistance to GVHD. Conditioning therapy
is likely to cause some epithelial tissue injury, with produc-
tion of proinflammatory cytokines [31,32] and chemokines,
adhesion molecule upregulation on endothelial cells, and
hence T cell migration into the GVHD target tissues. By
waiting sufficiently long for the recipient to recover from
conditioning treatment, it may be possible to induce GVH
reactions that are confined within the lymphohematopoietic
system only. This type of alloresponse is highly desirable, as
it may be associated with GVL reactions [28]. Consistent
with these results, DLI have been used to induce remissions
in patients with chronic myelogenous leukemia who relapse
after allogeneic BMT. Although many of these patients
develop GVHD, it has been suggested that the incidence
and severity may be lower than expected for the large num-
ber of donor T cells given [33–35].
A second factor that may confer resistance to GVHD
may be the mixed chimeric state itself. Consistent with a
role for host hematopoietic cells in suppressing GVHD, the
initial presence of host hematopoietic elements has been
shown to mitigate the severity of GVHD in rodents [29,36].
“Natural suppressor” cells, which recover first from host
marrow in mixed marrow recipients [37] and possibly other
host-derived cell populations, may play a role in this effect.
The spontaneous development of mixed chimerism has been
associated with a lower incidence of GVHD (and a higher
incidence of graft failure) in some human studies of conven-
tional allogeneic BMT [38,39], but not in others [40].
Because animals receiving DLI demonstrate lymphohe-
matopoietic GVH reactions that convert them to full
chimeras, any regulatory cell populations that play a role in
preventing GVHD must have highly restricted activities,
perhaps preventing adhesion molecule upregulation or the
production of critical cytokines by donor T cells, without
globally preventing GVH alloreactivity. 
Preliminary data from a pilot clinical trial that we have
initiated based on the murine studies reported here are
strongly supportive of the possibility that mixed chimerism is
associated with increased resistance to GVHD. Less severe
GVHD than expected has been observed in patients receiv-
ing allogeneic BMT after conditioning with anti-thymocyte
globulin, high-dose CP, and thymic irradiation, followed by
DLI on day 35 or later [41–43]. Similar to the murine studies
described here, these patients develop mixed chimerism ini-
tially, and the delayed administration of DLI can convert
them to complete donor chimeras without causing GVHD.
Preliminary results have shown striking anti-lymphoma
responses in these patients, even in the absence of GVHD
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[41,42], demonstrating that this approach can indeed be used
to separate GVHD from GVL. Our clinical study also
demonstrates that lasting, high-level, multilineage mixed
chimerism can be induced intentionally across MHC barriers
in adult humans receiving cells treated with nonmyeloabla-
tive conditioning protocol based on the strategy described
here. Other BMT regimens involving HLA-identical sibling
or matched-unrelated BMT after nonmyeloablative condi-
tioning with purine analog–containing combinations of
chemotherapeutic agents led to high levels of donor recon-
stitution (rather than lasting mixed chimerism) in recipients
of HLA-matched sibling marrow [44,45], but matched unre-
lated donor marrow failed to engraft in two of two patients
[46]. The dominant donor reconstitution and failure of
engraftment of matched-unrelated marrow transplants in
one of these studies [46] suggests that the host conditioning
used by these groups may be less immunosuppressive, and
perhaps more myelosuppressive, than our strategy, which
involves depleting T cells with antibody and thymocytes with
irradiation, along with CP for additional immunosuppression
and myelosuppression. Using a similar strategy, HLA-mis-
matched marrow engraftment is clearly achievable [42].
One potential toxic effect of lymphohematopoietic
GVH reactions might be atrophy of recipient lymphoid tis-
sues and associated GVH-induced immunodeficiency [47].
Indeed, we have previously shown that DLI administered to
mixed chimeras prepared with lethal conditioning induces
transient immunodeficiency without clinical GVHD, with
eventual recovery of immune function in most animals [11].
Although we did not see clear evidence of lymphoid atrophy
in most long-term DLI recipients at the time of death in
this study, further studies are needed to evaluate the degree
of immune responsiveness remaining in these mice.
In summary, the studies presented here demonstrate that
lasting, low-level multilineage mixed chimerism can be
induced across complete histocompatibility barriers in mice
using a nonmyeloablative conditioning regimen that consists
of T-cell–depleting mAbs, CP, and thymic irradiation and
that administration of DLI at 5 weeks and later can convert
the mixed chimeras to full donor-type chimeras without
causing clinically evident GVHD. The incidence of
chimerism and the ability of DLI to cause this conversion in
fully mismatched strain combinations is somewhat variable,
and further studies are needed to determine the outcome of
this approach in more clinically relevant, less disparate strain
combinations. In view of results (to be presented elsewhere)
showing that earlier DLI can have adverse consequences,
including loss of chimerism or the development of GVHD,
additional work is needed to elucidate the kinetics and mech-
anisms of the development of host-vs.-graft tolerance and of
resistance to GVHD by day 35 in this model. However, the
relative safety with which DLI can be administered at late
times post-BMT while mediating potent lymphohematopoi-
etic graft-vs.-host responses in mixed chimeras prepared with
nonmyeloablative conditioning suggests a rational approach
to separating GVHD from GVL.
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